Quick Links: Skip to main page content
Skip to Search
Skip to Topics Menu
Skip to Common Links
U.S. Food & Drug Administration
Follow FDA
En Español
Search FDA
Home
Food
Drugs
Medical Devices
Radiation-Emitting Products
Vaccines, Blood & Biologics
Animal & Veterinary
Cosmetics
Tobacco Products
New Pediatric Labeling Information Database - Detail
FDA Home
Pediatrics
New Pediatric Labeling Information Database
Detail
-
Please note:
JavaScript must be enabled for this application to work properly.
Check your settings
if you are unsure if your JavaScript is enabled.
Pediatric Labeling Date:
03/25/2008
Trade Name:
Reyataz
Generic Name or Proper Name (*):
atazanavir
Indications Studied:
HIV in 6 years and older
Label Changes Summary:
Extended indication from adults to children 6 years and older The safety, activity, and pharmacokinetic profiles in pediatric patients ages 3 months to < 6 years have not been established. Atazanavir should not be administered to pediatric patients below the age of 3 months due to the risk of kernicterus Dosing is based on body weight or body surface area not to exceed adult dose Adverse events (AEs) are generally similar to those seen in adults Information on dose, AEs, PK parameters, lab abnormalities, and clinical study
Product Labeling:
Labeling
BPCA(B) and PREA(P):
B, P
Sponsor:
Bristol-Myers Squibb
NNPS:
FALSE'
Therapeutic Category:
Antiviral
-
-